甘露醇联合尼可刹米、纳洛酮治疗慢性阻塞性肺疾病呼吸衰竭并发轻型肺性脑病的临床观察
详细信息 查看官网全文
- 英文论文题名：Combination of mannitol,brake,naloxone in patients with chronic obstructive pulmonary disease respiratory failure complicated with light clinical observation of pulmonary encephalopathy
- 论文作者：曹晓红 ; 郑丽琴 ; 张新日
- 英文论文作者：Cao Xiaohong ; Zheng Liqin ; Zhang Xinri
- 年：2017
- 作者机构：山西省汾阳医院呼吸科;山西医科大学第一医院呼吸科;
- 论文关键词：甘露醇 ; 纳洛酮 ; 尼可刹米 ; 肺性脑病
- 英文论文关键词：mannitol ; nikethamide ; naloxone ; pulmonaryencephalopathy
- 会议召开时间：2017-05-26
- 会议录名称：2017年《中国组织化学与细胞化学杂志》临床研讨会论文集
- 语种：中文
- 分类号：R563;R747.9
- 学会代码：ZHXB
- 会议名称：2017年《中国组织化学与细胞化学杂志》临床研讨会
- 会议地点：中国湖北武汉
- 主办单位：《中国组织化学与细胞化学杂志》社有限公司
- 学会名称：《中国组织化学与细胞化学杂志》社有限公司
- 页数：1
- 文件大小：118k
- 原文格式：O
- 会议级别：全国
摘要
观察甘露醇联合尼可刹米、纳洛酮治疗慢性阻塞性肺疾病呼吸衰竭并发轻型肺性脑病的临床疗效。方法:将2015年1月到2016年6月我科慢性阻塞性肺疾病呼吸衰竭并发轻型肺性脑病患者36例随机分为治疗组18例,对照组18例。两组均予持续低流量吸氧,积极控制感染,解痉平喘,止咳化痰,保持气道通畅,维持酸碱水、电解质平衡,营养支持等综合治疗;结果:治疗组24h、72h后在症状、格拉斯哥评分、血气分析的改善方面优于对照组(P<0.05),而NSE在治疗前后变化不大,治疗组和对照组间无差异(P>0.05)。结论:甘露醇联合尼可刹米、纳洛酮治疗慢性阻塞性肺疾病呼吸衰竭并发轻型肺性脑病明显优于对照组,且安全、有效,值得推广。
Objective:To observe the clinical efficacy of mannitol and nike thamideandnaloxone treatmentedon AECOPD complicate dbyrespiratory Failure with light pulmonaryencephalopathy.Methods Thirty-sixpatients of AECOPD complicated by respiratory failure with light pulmonaryencephalopathy in our depart ment from Jan 2015 to Jun 2016 were randomly divided in toeighteen treatment group and eighteen controlgroup.Allpatients were continued lowdischarge Oxygeninhalation,actived to controlinfections,spasmolysisandrelievingasthma,relievingcoughandreducingsputum,keepedairway expedite,maintainedacid-basewaterelectrolytebalance,nutritious support in comprehensive treatment;Results Clinicalsymptoms,Glasgow Coma Scale(GCS) and Blood-gasanalysis indices(pHvalue,PaCO_2 andPaO_2) were significantlyimprovedin treatment group.Compared with controlgroup in sametime-points(24h and 72h),the differences were statistically significant(all P<0.05).ButNSEchangedhardlyinpretherapyandpost-treatment,the difference was not statistically significant(P > 0.05) in NSE of two groups.Conclusion:The efficiency and safety of mannitoland nike thamideandnaloxone treatment edonchronicobstructivepulmonary disease(AECOPD) complicatedbyrespiratory Failure with light pulmonaryencephalopathyaresatis factory.Itisworth to popularize
Objective:To observe the clinical efficacy of mannitol and nike thamideandnaloxone treatmentedon AECOPD complicate dbyrespiratory Failure with light pulmonaryencephalopathy.Methods Thirty-sixpatients of AECOPD complicated by respiratory failure with light pulmonaryencephalopathy in our depart ment from Jan 2015 to Jun 2016 were randomly divided in toeighteen treatment group and eighteen controlgroup.Allpatients were continued lowdischarge Oxygeninhalation,actived to controlinfections,spasmolysisandrelievingasthma,relievingcoughandreducingsputum,keepedairway expedite,maintainedacid-basewaterelectrolytebalance,nutritious support in comprehensive treatment;Results Clinicalsymptoms,Glasgow Coma Scale(GCS) and Blood-gasanalysis indices(pHvalue,PaCO_2 andPaO_2) were significantlyimprovedin treatment group.Compared with controlgroup in sametime-points(24h and 72h),the differences were statistically significant(all P<0.05).ButNSEchangedhardlyinpretherapyandpost-treatment,the difference was not statistically significant(P > 0.05) in NSE of two groups.Conclusion:The efficiency and safety of mannitoland nike thamideandnaloxone treatment edonchronicobstructivepulmonary disease(AECOPD) complicatedbyrespiratory Failure with light pulmonaryencephalopathyaresatis factory.Itisworth to popularize
引文
[1]全国第三次肺心病专业会议.肺性脑病的诊断和临床分级标准[S].中华结核和呼吸杂志,1981;4:62
[2]何莲,雷宇.肺脑合剂联合BiPAP无创呼吸机治疗肺性脑病的疗效观察[J].吉林医学,2011,32(21):4360-4361
[2]何莲,雷宇.肺脑合剂联合BiPAP无创呼吸机治疗肺性脑病的疗效观察[J].吉林医学,2011,32(21):4360-4361